If it could be shown that administered antibodies can detect tumor endothelial cells intravenously, the current presence of FSH receptor on the top of these cells in a wide range of tumors makes it a potential target for both tumor imaging and therapy. As proven in Physique 4 in the Supplementary Appendix, FSH-receptor density on the gonadal endothelial cells is much lower than that in tumors, and for that reason, it could be possible to find a therapeutic window so the gonadal vessels aren’t substantially affected.Blood samples were collected for viral sequencing at every study visit. Among patients who experienced viral breakthrough, for all samples that the HCV RNA level was greater than 1000 IU per milliliter , the NS3/4A region of the HCV genome was analyzed through population sequencing. Rates of relapse through the follow-up period were calculated for the patients in each group who also had undetectable HCV RNA at that time of which their assigned treatment was completed . In the T12PR24 and T12PR12 groupings, relapse rates were based on data from the patients who had a rapid virologic response at treatment week 4 and undetectable HCV RNA amounts through week 20 or through week 10 and who finished therapy. Statistical Analysis The principal end point was the proportion of patients in each group who had undetectable plasma HCV RNA levels 24 weeks after the completion of therapy .